I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $168.83M | ||||
Company |
Location |
Date |
Amt. (M) |
Details |
| | ||||
Acadia Pharmaceuticals Inc. |
San Diego |
6/13 |
$3 |
Acadia raised $3M in a follow-on closing that included new equity investment by funds managed by Coastview Capital, bringing the total raised to $28M |
|
||||
Affymax Inc. |
Palo Alto, Calif. |
6/27 |
$20 |
Affymax raised $20M in a private round led by Apax Partners & Co.; other investors were Sprout Group and MPM Capital |
|
||||
Can-Fite BioPharma Ltd. |
Petach Tikva, Israel |
6/11 |
$12 |
Can-Fite raised a total of $12M in a financing round begun last year; investors were BPW Israel Ventures LLD, Giza Venture Capital, The Yozma Group, Ascend Technology Ventures, Vitalife and individual physicians |
|
|
|||
CyThera Inc. |
San Diego |
6/4 |
$2 |
CyThera raised $2M in venture capital financing |
|
||||
Encelle Inc. |
Raleigh, N.C. |
6/10 |
$2 |
Encelle raised more than $2M in the final tranche of a Series D preferred stock offering led by North Carolina Enterprise Fund and Intersouth Partners |
|
|
|||
EpiGenesis Pharmaceuticals Inc. |
Princeton, N.J. |
6/6 |
$23 |
EpiGenesis raised $23M in a Series A round led by Care Capital; other investors were Investor Growth Capital, Boston Millennia Partners, Merrill Lynch Ventures, Technology Partners and NJTC Venture Fund |
|
||||
Fluorous Technologies |
Pittsburgh |
6/27 |
$3 |
Fluorous raised $3M after completing a Series A round from corporate and angel investors, including Albany Molecular Research Inc., Alfred Bader, Innovation Works, Fairview Funds and others |
|
||||
GlobeImmune |
Aurora, Colo. |
6/18 |
$8 |
GlobeImmune raised $8M in a Series A venture financing round; investors included HealthCare Ventures LLC, Morgenthaler Ventures and Sequel Venture Partners |
|
||||
Hawaii Biotech |
Honolulu |
6/9 |
$4.4 |
Hawaii Biotech raised $4.4M in a Series A round co-led by International Venture Fund and HMS Hawaii |
|
||||
Hydro Med Sciences Inc. |
Cranbury, N.J. |
6/27 |
$12 |
Hydro Med raised $12M through a placement of Series B preferred stock; investors were Corporate Opportunities Funds, Wheatley Partners and Paladin Labs Inc. |
|
||||
Iliad Chemicals Pty. Ltd. |
Sydney, Australia |
6/27 |
A$2.25 (US$1.5) |
Iliad raised US$1.5M in early stage funding from Start-up Australia Ventures Pty. Ltd. and the Australian government's Biotechnology Innovation Fund |
|
||||
ImmunoBiology Ltd. |
Cambridge, UK |
6/18** |
£0.72 (US$1.2) |
ImmunoBiology raised US$1.2M in a round led by Generics Asset Management Ltd. |
|
||||
KaloBios Inc. |
Mountain View, Calif. |
6/24 |
$4 |
KaloBios raised $4M in a seed round with Sofinnova Ventures and Alloy Ventures |
|
||||
mtm laboratories AG |
Heidelberg, Germany |
6/4** |
€9 (US$10.56) |
mtm raised US$10.56M in a second roundled by HBM BioVentures AG; other investors were Heidelberg Innovation and Mannheim Holdings LLC |
|
||||
Nautilus Biotech |
Paris |
6/23 |
€4 (US$4.57) |
Nautilus raised US$4.57M in a financing that included Matignon Technologies, Rothschild Venture Partners, FCJE and Pre-IPO Invest |
|
||||
Prestwick Pharmaceuticals Inc. |
Washington, D.C. |
6/19 |
$15 |
Prestwick raised $15M in a first round financing co-led by BioAsia Investments and Sofinnova Ventures, with added investments from Atlas Venture and BA Venture Partners |
|
|
|||
Q-RNA Inc. |
New York |
6/13 |
$2.6 |
Q-RNA raised $2.6M in a financing with investors Durand Venture Associates, Wheatley Partners and Double D Venture Fund |
|
||||
QuatRx Pharmaceuticals Co. |
Ann Arbor, Mich. |
6/10 |
$28 |
QuatRx raised $28M in a Series C round led by MPM Capital; other investors were InterWest Partners, Frazier Healthcare Ventures and TL Ventures |
|
|
|||
Tiosyn Corp. |
Burlington, Vt. |
6/2 |
$12 |
Triosyn raised $12M in a private equity financing; investors were SL Ventures, CDP Capital - Technology Ventures, BDC Venture Capital and Innovatech du Grand Montreal |
|
|
|||
II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $10M | ||||
Company |
Partner (Country) |
Amt. (M) |
Triggering Event |
Details (Date) |
| | ||||
Digital Gene Technologies Inc.* |
Elan Corp. plc (Ireland) |
$1 |
Investment |
Digital Gene earned the investment by identifying 10 validated vaccine targets derived from its joint research in intestinal M-cell biology (6/20) |
|
||||
ImClone Systems Inc. (IMCLE) |
Merck KgaA (Germany) |
$3 |
Milestone payment |
ImClone received the payment for progress in development of Erbitux for non-small-cell lung cancer (6/26) |
|
|
|||
Ligand Pharmaceuticals Inc. (LGND) |
GlaxoSmithKline plc (UK) |
$1 |
Milestone payment |
Ligand earned the $1M as a result of GSK's decision to continue Phase I development of 501516, a peroxisome proliferation activated receptor modulator to treat dyslipidemias (6/5) |
|
||||
TGN Biotech Inc.* (Canada) |
Foragen Technologies Management Inc. (Canada) and Innova- tech Quebec, Fondaction CSN (Canada) |
C$5.35 (US$4) |
Investment |
TGN Biotech received an investment of US$4M (6/17) |
|
||||
Tranzyme Inc.* |
Shin Nippon Biomedical Laboratories Group (Japan) |
$1 |
Equity investment |
Shin Nippon invested in $1M in Tranzyme's stock; the companies also initiated discussions to establish an alliance (6/5) |
|
||||
| | ||||
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
* Denotes privately held company. | ||||
** Denotes the date the item ran in BioWorld International. | ||||
ND = Not disclosed. | ||||
